Eisai’s Halaven Receives Final Draft “No” From NICE

In final draft guidance given yesterday, the National Institute for Health and Clinical Excellence (NICE) announced that they are not recommending Eisai’s Halaven (eribulin) for the treatment of locally-advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens for advanced disease. Although the evidence shown to NICE’s independent

Continue Reading

NICE Reject Breast Cancer Drug Faslodex

England and Wales’ cost watchdog, NICE, yesterday reiterated their assessment that AstraZeneca’s breast cancer drug Faslodex does not represent good use of NHS funds and has not been proven to be better than current treatments. The National Institute for Health and Clinical Excellence (NICE) has published their  final appraisal determination, saying that they do not

Continue Reading

Pradaxa Receives Final Draft OK From NICE

Final draft guidance released from the UK’s National Institute for Health and Clinical Excellence (NICE) recommends the use of Boehringer Ingelheim’s Pradaxa (dabigatran) for the prevention of stroke and systemic embolism in people with atrial fibrillation. In addition, the draft guidance recommends that the decision on whether to start treatment with Pradaxa should be made

Continue Reading

NICE Draft OK for Eli Lilly Diabetes Drug

The UK’s National Institute for Health and Clinical Excellence (NICE) have issued an initial recommendation of approval for the use of Eli Lilly’s Bydureon (exenatide prolonged-release suspension for injection) in triple-therapy options for people with type 2 diabetes, when control of blood glucose remains or becomes inadequate. NICE commented that Bydureon improves glycaemic control in

Continue Reading

Disappointment as NICE Rejects Skin Cancer Drug

The conclusion by the UK’s National Institute for Health and Clinical Excellence (NICE) to reject Bristol-Myers Squibb’s new melanoma drug Yervoy has been greeted with disappointment by the company and patient groups. In a provisional draft guidance published earlier today, NICE decided against recommending payment by the UK’s National Health Service (NHS) of Yervoy (ipilimumab)

Continue Reading

NICE Issues Final Draft OK For Brilique

The UK National Institute for Health and Clinical Excellence (NICE) has issued a final draft guidance recommending the use of AstraZeneca’s antiplatelet drug Brilique (ticagrelor) in the treatment of acute coronary syndromes (ACS). Every year, around 200,000 people in England are diagnosed with acute coronary syndromes, which cover a range of conditions from unstable angina

Continue Reading

NICE Rejects BMS’ Orencia For RA

NICE (the National Institute for Health and Clinical Excellence) has issued final guidance rejecting the use of Bristol-Myers Squibb’s Orencia (abatacept) as a second-line treatment for rheumatoid arthritis (RA). The guidance says that the use of Orencia is not recommended in combination with methotrexate for treating RA in adults whose disease has responded inadequately to

Continue Reading

Novartis MS pill rejected by NICE

The decision by the UK’s cost watchdog to reject Novartis’ Gilenya, the first pill to treat multiple sclerosis, has been greeted with dismay by the company and patient groups. In provisional draft guidance published this morning, the National Institute for Health and Clinical Excellence has decided against recommending payment by the National Health Service for

Continue Reading